

Trends in Technology Usage for Parkinson's Disease Assessment: A Systematic Review

Ranadeep Deb¹, Ganapati Bhat^{2,*}, Sizhe An³, Holly Shill⁴ and Umit Y. Ogras³

¹Analog Devices, Greensboro, NC, USA

² School of Electrical Engineering and Computer Science, Washington State University, Pullman, WA, USA

³ Department of Electrical and Computer Engineering, University of Wisconsin-Madison, Madison, WI, USA

⁴ Lonnie and Muhammad Ali Movement Disorder Center, Phoenix, AZ, USA

Abstract

Parkinson's disease (PD) is a neurological disorder with complicated and disabling motor and non-motor symptoms. The complexity of PD pathology is amplified further due to its dependency on patient diaries and the neurologist's subjective assessment of clinical scales. This challenge can be addressed by the advances in mobile technology, which can enable objective, accurate, and continuous patient monitoring. Indeed, a significant amount of recent work explores new cost-effective and subjective assessment methods of PD symptoms. For example, smart technologies, such as wearable sensors, have been used to analyze a PD patients' symptoms to assess their disease progression and even to detect signs in their nascent stage for early diagnosis of PD.

This review focuses on the use of modern wearable and mobile equipment for PD applications in the last decade. Four significant fields of research were identified: Assistance to Diagnosis, Prognosis or Monitoring of Symptoms and their Severity, Predicting Response to Treatment, and Assistance to Therapy or Rehabilitation. This study starts with 31,940 articles published between January 2008 and December 2019 in the following four databases: Pubmed Central, Science Direct, IEEE Xplore and MDPI. A total of 976 papers are manually investigated and included in this review after removing unrelated articles, duplicate entries, publications in languages other than English, and other articles that did not fulfill the selection criteria. Our analysis shows that the numbers of published papers every year has increased at a constant rate from 2008 to 2015, while the rate of increase has significantly grown from 2016 to 2019. Majority of the papers (62%) were published in the last four years, and 21% papers in just 2019. In terms of the symptoms, gait and tremor are two major ones that researchers have focused on. The trend shows the growing interest in assessing Parkinson's Disease with wearable devices in the last decade, particularly in the last 4 years. Our automated script makes the review easily reproducible for publications published in the future.

Index Terms

Parkinson's disease, Wearable devices, Remote monitoring, Digital health, Biopotential devices, Diagnosis, Prognosis, Taxonomy

I. INTRODUCTION

Parkinson's disease (PD) is a complex neurodegenerative disorder that affects patients' and their caregivers' overall quality of life (QoL). Approximately 60,000 individuals in the United States are diagnosed with PD each year, while more than 10 million people are living with PD worldwide [1], [2]. PD is often seen together with many significant motor signs, such as tremor, rigidity, bradykinesia, hypokinesia, postural instability, and gait difficulties. While its clinical diagnosis is usually based on these motor symptoms, many non-motor symptoms also manifest themselves with the disease. These non-motor symptoms are commonly evident and sometimes more disabling than motor symptoms. Common non-motor signs of the disease are cognitive impairment, reduced ability to smell, dementia, depression, and emotional changes. It is a progressive disorder whose symptoms become more noticeable with age.

The current practice for assessing the motor and non-motor symptoms of PD patients is a neurological examination, during which a neurologist watches the patient perform specific tasks. Neurologists assign scores to the tasks performed by the patient as described by the Unified Parkinson's Disease Rating Scale (UPDRS) [3] or its updated version, the Movement Disorder Society-sponsored revision of the UPDRS (MDS-UPDRS) [4]. Another rating scale, the Hoehn and Yahr scale (HY) [5] assigns an overall score out of 5 to the patient based on their clinical stage. These clinical scales are subjective and can lead to high inter-rater variability among neurologists and clinics. Similarly, the clinical assessment relies also on the symptoms' progression described in the patient's diary. The credibility of such reports is limited by subjectivity and recall bias of the patient [6], [7]. Second, the cost of current treatment approaches is high. Medication alone can cost \$2,500 a year, while a corrective surgery, like Deep Brain Stimulation (DBS), costs up to \$100,000 per person [1]. For example, imaging equipment, such as magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET), are used to assist the neurologist in making an objective and more accurate diagnosis [8]. High equipment costs factor into the expenses of diagnosis and treatment of Parkinson's Disease [9].

Advances in mobile computing technologies facilitate long-term objective measurement of symptoms. Hence, new systems based on mobile technology can enable a wide range of monitoring, diagnosis, and rehabilitation applications [10]–[14]. Indeed, the number of publications that report using wearable and mobile technology for PD research increased by 100 times between

2008 and 2019, as the results presented in Section V. Popular devices include inertial measurement units (IMUs), force and pressure plates, biopotential sensors, and optical motion capturing systems. IMUs usually include accelerometer and gyroscope sensors, which can record essential data for analyzing the symptoms. Similarly, force sensors in a force plate provide information about the patient’s posture and balance. As a complementary modality, electroencephalogram (EEG) and electromyogram (EMG) sensors measure neural activity and muscular response, respectively. In contrast, optical motion capturing systems like VICON and Microsoft Kinect analyze patients’ body motion in their ambulatory environment. Interconnection of these sensors has also become straightforward with the growing use of communication protocols, such as Zigbee and Bluetooth.

A large number of recent studies investigated the use of wearable sensors and other technologies to assess the symptoms of a patient suffering from neurological disorders [15]. There is also a growing interest in getting an unbiased analysis of the efficacy of technology-based devices that can be used in scientific research of health monitoring and clinical practices [16]. For example, [16] reviewed 168 articles after searching the PubMed database and grouped the studies based on the type of device used. They classified the devices as (i) ‘recommended’, (ii) ‘suggested’ or (iii) ‘listed’ based on the following criteria: (1) used in the assessment of Parkinson’s disease, (2) used in published studies by people other than the developers, and (3) successful clinimetric testing. They concluded that objective sensing technology is gaining attention in the study of Parkinson’s Disease, but the clinimetric properties and testing of the devices remain a controversy. They surmised that PD symptoms like postural control, bradykinesia, tremor, freezing, dyskinesia, gait, and daily activity/physical activity could be objectively measured using the reviewed devices. Applications of wearable technology to the assessment of PD symptoms has also increased in recent years [17]. Wearable sensors have shown promise in PD diagnosis and management, as well as for other pathology [18]–[21]. For example, [21] discuss how wearable and mobile technologies could improve the management of Essential Tremor (ET), one of the most common movement disorders that impact millions of people worldwide. The study proposed 7 different areas in which mobile and wearable technology can improve the clinical management of ET and review the current state of research in these areas. The authors conclude that the presence of mobile and wearable technology everywhere could be leveraged to improve the quality of life of the patients if clinicians, engineers, and computer scientists work together on addressing the current knowledge gaps.

This paper presents a systematic review of mobile technology use in the PD context by analyzing articles published between January 1, 2008, and December 31, 2019. An electronic database search in Pubmed Central, Science Direct, IEEE Xplore, MDPI is performed to retrieve all articles related to Parkinson’s Disease (with the keyword “Parkinson”). This search yields 25,600 articles after removing surveys and articles written in a language other than English. Then, the articles are filtered by applying one blocks of keywords related to the disease, such as “Tremor” and “Freezing of gait (FoG)”. Similarly, the remaining blocks of keywords filter articles that employ non-human subjects, out of scope technologies, and devices, as detailed in Section IV-B. After the automatic filtering using the keywords, these articles are inspected and classified manually to identify the following aspects: (1) the application areas of the proposed solution, (2) the symptoms measured for the application, (3) the devices used for measuring the symptoms, and (4) the sensors included in the devices. The papers under study and our classification are saved in a spreadsheet and released to the public at <https://bit.ly/2HVwKZ0>. The spreadsheet can be updated as new solutions are developed in the future. Hence, it can serve as a platform for technology professionals and clinicians to find innovative developments in the area. Furthermore, this spreadsheet can be used by researchers working in this area to compare their work with the other existing work in their field. The manually labeled data from this spreadsheet can also enable automatic classification of papers studying PD symptoms with modern devices.

We have also developed an automated filtering framework for articles focusing on PD assessment with novel technologies based on their content in Title, Abstract, and Keywords (TAK). The filtering criteria are developed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard [22]. Our criteria also follow the PICO (Patient, Intervention, Comparison, Outcome) principles [23]. Manual filtering is limited by time and subjectivity, which can be avoided by our filtering framework. It can objectively select the relevant articles for any systematic review or find the related literature in a specific field of work. It can also detect duplicate items across multiple databases and filter them out. *The automated script makes the review easily reproducible for publications published in the future.*

We then reviewed each article as follows:

- Analyze the trends in the use of technology for PD research. For example, we use the data to identify the most popular application areas and the areas that receive increasing attention (Section II),
- Analyze the devices used in each application area, and how the use of devices has progressed in the last decade (Section III),
- Analyze the symptoms measured in each application area and determine the most commonly used devices for measuring the different traits (Section V-A),
- Examine the overall trend of research in this field and how it progresses in the coming years (Section V-B, Section V-C).

II. APPLICATION AREAS

Mobile technology can be used to track symptoms that can be used to assess the progression of a PD patient. These symptoms, referred to as cardinal PD features, are divided into motor symptoms and non-motor symptoms, as shown in Table I. The motor symptoms are the movement impairments caused due to Parkinson’s Disease. The motor symptoms are traditionally considered

109 as tremor, rigidity, bradykinesia and postural instability. Additionally, abnormalities in limb movements like hand rotation,
 110 finger tapping, and arm angle etc., are also considered as motor symptoms. In contrast, non-motor symptoms include a large
 111 variety of cardinal features, such as sleep disturbance, cognitive activity, fatigue, dementia, and psychiatric impairments, as
 112 listed in the second column of Table I. Finally, mixed symptoms, such as speech and swallowing, exhibit a combination of motor
 113 and non-motor activities. Figure 1 shows the number of papers that measure the different motor and non-motor symptoms.
 114 Gait abnormalities, including FoG are the most common symptoms measured, followed by tremor. Movement problems like
 115 bradykinesia and dyskinesia are also common symptoms in PD patients, and many research articles use modern measurement
 116 techniques to monitor these symptoms.

117 Mobile monitoring of motor and non-motor symptoms can be used in four major application areas in the PD research context:
 118 Diagnosis, Prognosis/Monitoring the Severity of Symptoms, Predicting the Response to Treatment, and Rehabilitation. These
 119 application areas are chosen based on previous reviews on PD [8], [17]. The rest of this section reviews these application areas.

TABLE I: Different domains of assessment of Parkinson’s Disease using new technologies

Signs and Symptoms		
Motor Signs and Symptoms	Non-motor Signs and Symptoms	Mixed Signs and Symptoms
Gait	EEG abnormalities	
Limb movements	Cognitive activity	
EMG abnormalities	Depression	
FoG	Dementia	
Tremor	Heart rate	Speech topics
Activities of Daily Living (ADL)	Emotions	Swallowing
Bradykinesia and Dyskinesia	Fatigue	
Posture	Sleep topics	
Balance	Blinking	
Nocturnal Hypokinesia	Facial expression	
Handwriting	Breath	
Saccades	Cortical activity	




Fig. 1: Number of publications between 2008-2019 that measure each symptom.

120 A. Diagnosis

121 The diagnosis of Parkinson’s Disease relies on the clinical assessment of the motor and non-motor symptoms by neurologists [24]. Neurologists observe the patients while they perform specific tasks. Then, they assign a score according to one
 122

of the standard scales: Unified Parkinson’s Disease Rating Scale (UPDRS) [3], its updated version, the Movement Disorder Society-sponsored revision of the UPDRS (MDS-UPDRS) [4], or the Hoehn & Yahr scale [5]. The clinical information derived from these rating scales is subjective. Hence, it leads to inter-rate variability and also intra-rate variability [8], [17]. Moreover, the equipment used to supplement the clinical assessment is expensive imaging tools like SPECT, PET, or MRI. Since early and accurate diagnosis is important, current techniques can be augmented with objective and cost-effective alternatives enabled by mobile technology. Therefore, recent work has used wearable sensors and other portable technology in the diagnosis of PD. These devices can provide objective measures for PD diagnosis that help in standardizing assessment [25]–[27]. Many researchers have also been able to use wearable sensors and other devices to differentiate PD patients and healthy controls in lab experiments [25], [26], [28].

In summary, mobile technology is used in the following sub-categories of PD diagnosis:

- Early diagnosis of patients with Parkinson’s disease
- Detecting Parkinsonian symptoms in people with untreated PD
- Differentiate patients with Parkinson’s disease from healthy controls or patients with a different neurological disorder
- Differentiate PD-related symptoms from similar symptoms but not caused by PD. For example, differentiating PD tremors from Essential Tremors (ET)

B. Prognosis/Monitoring the Severity of Symptoms:

Assessing the patient’s condition and severity of symptoms depend primarily on the clinicians’ judgment and the patient feedback from diaries and memory. The clinicians’ judgment is subjective [8], [17] while the patient’s diary and memory are limited by compliance and recall bias [6], [29], [30]. Since this approach may not be completely reliable, objective remote monitoring of PD symptoms is needed to assess disease progression, evaluate the severity of the symptoms, and continuously monitor the PD patients in unsupervised environments. To address these issues, recent work on PD prognosis focuses on the following areas:

- Home-based or remote monitoring of patients with PD
- Evaluating the progression of PD for a diagnosed patient
- Evaluating the severity of PD symptoms for a diagnosed patient

C. Predicting Response to Treatment:

To measure the efficacy of the treatment or the impact of the medication, clinicians rely on the patients’ recollection and their diaries, which can be subjective and unreliable. This problem motivated research on measuring the impact of a treatment, medication’s effectiveness in suppressing the PD symptoms, and assess their side effects. To this end, research on predicting response to treatment addresses the following issues:

- Measure the effect of treatment like Deep Brain Stimulation in suppressing the patient’s symptoms over time
- Measure the impact of a medication on the symptoms of the patient
- Measure the side effects of the medicine (e.g., levodopa induces dyskinesia)

D. Rehabilitation

Physiotherapy and other rehabilitation techniques are among the most common treatments for movement disorders like Parkinson’s Disease. Like medication, it is crucial to assess their efficacy. Additionally, it has been observed that cues and feedback are beneficial in assisting a PD patient. A system can provide rhythmic auditory cues, visual cues, or haptic cues to facilitate a patient’s movement. Such a system can be used for gait training or to assess limb movements. Vibration-based actuators and audio feedback are useful to sensitize a patient suffering from Rigidity, Freezing of gait (FoG), Tremor, or other symptoms. They can also help patients break out of the freeze even suppress the symptom. Mobile technologies that target therapy and rehabilitation can be divided into the following sub-categories:

- Audio, visual, or haptic cue for gait or movement training
- Sensory feedback to suppress a symptom like FoG or Tremor

III. TECHNOLOGY IN PARKINSON’S DISEASE RESEARCH

A number of device type and technologies are being used in the application areas presented in the previous section. We classify these devices into the following eight categories based on their form factor and sensing modalities.

Wearable: Many recent approaches employ wearable devices for health monitoring since they facilitate recording patients’ activity and symptoms. Wearable devices are ideal for monitoring since they are not limited to a specific location and they can be easily integrated into patient’s clothes [31]. Most commonly used wearable devices contain sensors, such as inertial measurement units (IMUs). The outputs of these sensors can be processed to analyze the body movement, gait, and symptoms such as tremors. Our study includes the following wearable technologies:

- 174 1) IMUs with integrated accelerometer, gyroscope, and magnetometer sensors,
- 175 2) Insole sensors containing force or pressure sensors that can measure the Ground Reaction Force (GRF),
- 176 3) Wearable devices that can measure neural responses and muscle activities using sensors such as EEG and EMG,
- 177 4) Sensors incorporated with clothes or gloves, such as strain or accelerometer sensors to measure hand tremor,
- 178 5) Other wearable devices like smart glasses or smart hats which can record specific parameters like patient's emotions.

179 **Biopotential Devices:** Devices that can measure the electrical signal (biopotentials) that are generated by the physiological
 180 processes in our body. The tools that fall under this category are Electroencephalogram (EEG), Electrocardiogram, Electro-
 181 cardiogram, Magnetoencephalogram, and Electrooculogram. The biopotential devices can either be standalone, such as a a
 182 16-lead EEG system, or in a wearable device with a single lead EMG sensor. When a biopotential device is integrated into a
 183 wearable device, it is included in both wearable and biopotential device categories.

184 **Cueing Devices:** Devices that are used to give feedback or cues to the patients to rectify their walk or to assist with their
 185 movement fall under this category. Headphones or speakers can be used to deliver auditory cues, and visual cues can be
 186 provided using a screen or a smart glass or even in a virtual reality environment. Vibration sensors or electrical stimulators
 187 have been utilized to give sensory feedback to patients.

188 **Optical Motion Tracker:** Devices that track motion of users with either radio frequency or optical signals fall under this
 189 category. For example, motion capturing systems, such as Microsoft Kinect and Vicon 3D, use structured light for analysis.
 190 Similarly, radar-based systems use radio frequency signals to monitor motion of subjects. A system of multiple IMUs, even
 191 camera-based 3D setups have also been used to capture the movement of a patient.

192 **Audio Recording:** A number of PD patients experience issues in swallowing or in their speech, as shown in Table I. Audio
 193 recording devices are used to analyze and monitor symptoms related to speech and swallowing. For instance, speech recording
 194 devices, such as microphones and smartphones, are used to record the speech tasks or the patients' voice to analyze the speech
 195 of the patient for diagnostic purposes [28], [32].

196 **Video Recording:** Video recording devices provide utility for PD monitoring since gait and motor issues are one of the most
 197 common symptoms in PD. For instance, patients' movements at home or during laboratory experiments are often recorded
 198 using a video camera to spot symptoms or to corroborate with predictions from other devices [33]–[35].

199 **Force/Pressure:** Force or pressure plates measure the force exerted by the patients' feet when they are walking. Therefore,
 200 they are useful to measure the quality of gait of the patient. Force or pressure sensors are also integrated into gait mats to
 201 measure the gait quality of a patient.

202 **Smartphone:** More researchers are trying to use the sensors present on-board a smartphone (accelerometer, gyroscope,
 203 magnetometer, GPS) for different analyses. Smartphone applications are also used to record the patients' mood, emotions
 204 and even to record the dosage or medicines. Additionally, the screen of the smartphone can be used to record handwriting, the
 205 microphone to record speech samples, and the camera to record patient movements.

206 **Other:** There are additional devices apart from the ones already mentioned which have also been used to assess a PD patient.
 207 We classify devices that do not fall into any of the above categories as "other". For example, for handwriting assessment,
 208 digitized tablets are used as a smart screen to write on during spiralography exams, and smart pens are used to record hand
 209 movement during writing. Virtual Reality and Augmented Reality-based solutions have also started becoming popular in PD
 210 applications.

211 IV. PAPER SELECTION AND CLASSIFICATION METHODOLOGY

212 This section presents our methodology to select and classify papers that use technology for PD research. Figure 2 shows
 213 an overview of the selection and classification process. We start with an automated search of articles from PubMed Central,
 214 Science Direct, IEEE Xplore, and MDPI databases. First, articles that are not relevant to our study are eliminated. For example,
 215 articles that include non-human subjects are excluded. In the next step, any duplicate articles that are included in the pool of
 216 papers are removed. Finally, the remaining articles are manually classified into one of the four application categories introduced
 217 in Section II. In addition, we also mark the mobile technology used in each study according to the categories presented in
 218 Section III. We describe each of these steps in more detail in the following sections.

219 A. Search Methodology

220 The first step in the review is to obtain articles that studied PD from 2008 to 2019. To this end, we perform an electronic
 221 database search of articles published between January 1, 2008, and December 31, 2019, in the PubMed Central, Science Direct,
 222 IEEE Xplore, and MDPI databases. These databases are chosen to allow both medical and engineering journals to be included
 223 in the search process [36]. The systematic search is performed by following the PRISMA guidelines [22]. The search query
 224 includes just the keyword "Parkinson" to keep the search broad. The title/abstract/keyword and year filters are used to provide
 225 more specificity. Moreover, only original articles published in English between January 2008 and December 2019, related to
 226 Parkinson's Disease are included in the pool of papers.

227 The search queries and the number of hits in each database are shown in Table II. A total of 31,940 articles are obtained
 228 from the search query, of which 13,070 are from PubMed Central, 16,292 are from Science Direct, 1971 are from IEEE Xplore,

TABLE II: Search queries used for each database

Database	Query	Years	Hits
Pubmed Central	parkinson[Body - Key Terms] OR parkinson[Abstract] OR parkinson[Title]	2008 - 2019	13070
Science Direct	“parkinson” in Abstract OR Keyword OR Title	2008 - 2019	16292
IEEE Xplore	“parkinson” in Abstract OR Keyword OR Title	2008 - 2019	1971
MDPI	“parkinson” in Abstract OR Keyword OR Title	2008 - 2019	938

229 and 938 articles are from MDPI. Next, the articles that are not in English or are review articles themselves are removed from
 230 the pool of papers. 25,600 articles were left after the process of excluding non-English and review articles. The Title, Authors,
 231 Publication Title, Year of Publication (YOP), Keywords, Abstract, Keyword, and DOI are accumulated for all of the 25,600
 232 entries. This database is fed to the filtering step to exclude articles that are out of our scope.

233 B. Filtering Methodology

234 Information collected from the four databases is used as input for an automated filtering script written in Python. Based
 235 on the PICO strategy [22], the script uses four keyword blocks adapted from [37] to implement the selection strategies and
 236 the exclusion criteria. The first keyword block has ten keywords related to the disease, followed by the second block of 7
 237 keywords to exclude studies conducted on non-human subjects, as shown in Figure 3. The next set of keyword blocks filter
 238 the papers based on the devices used. Specifically, the third keyword block has 66 technology devices commonly used for
 239 Parkinson’s Disease assessment. Finally, the last keyword is used to exclude 11 technologies that are unsuitable outside the
 240 clinic use. The excluded technologies include MRI, deep brain stimulation, PET, neuroimaging, and SPECT. The complete list
 241 of all keywords is provided in Appendix C.




Fig. 2: Flow diagram of the systematic review process to new technologies used in assessment of Parkinson’s Disease in the last ten years

242 A Python script is used to automate the filtering process. The script goes through each article’s Title, Abstract, and Keywords
 243 (TAK). It compares them with the four keyword blocks to objectively determine if the material is relevant to our review or
 244 can be excluded, as shown in Figure 3. The first keyword block is applied at the beginning of the process. If the TAK search
 245 indicates that the article is not related to PD, further evaluations are skipped. The second keyword block is then applied to
 246 exclude studies with non-human subjects, such as rats or monkeys. This keyword block also determines the clinical feasibility
 247 of the studies. Similarly, the third and the fourth keyword blocks are used on the remaining list of articles to select or exclude
 248 them based on the devices used.

249 The automated filtering process excluded 23,225 articles from the complete list of 25,600 articles. Specifically, the first
 250 keyword block included 7,659 articles relevant to the symptoms that we consider in this review. The second keyword block
 251 excluded 4377 articles from the 7,659 articles since they use non-human subjects, thus leaving 3,282 articles for further filtering.
 252 Similarly, the third and fourth keyword blocks excluded 907 articles as they involved studies with technologies that are out
 253 of our scope. The full list of the keywords are provided in Appendix C. Finally, the script removes duplicate entries, leaving
 254 2282 articles.

255 The Python code used for filtering and removing the duplicate articles will be made available to the public. Sharing the
 256 tools and data used in this study will facilitate future work with more articles published after 2019.

257 C. Classification Methodology

258 The articles obtained after the automated filtering process are manually analyzed to classify the application area and
 259 technology used in each study. We first read the title, abstract, and keywords to understand the main application area. Specifically,
 260 we choose one of the four application areas described in Section II. We also denote the symptoms (Table I) analyzed by the
 261 articles. If the application area or symptoms cannot be extracted from the TAK review, we read the entire paper to classify
 262 the application area and the symptoms accurately. The devices and technology used by the studies are also categorized using
 263 a similar procedure.

264 As part of the manual classification, we also exclude any articles that are out of scope. For example, some articles use
 265 specific terms, such as sensor and acceleration, although they are out of scope. Similarly, some articles that use “ECG” to
 266 monitor “Wolff-Parkinson-White (WPW) syndrome” gets accidentally included by the script, even though Wolff-Parkinson-
 267 White (WPW) syndrome is not related to PD. We manually exclude such articles from the final list of classified items. Overall,
 268 after manual inspection 976 out of 25,600 articles were identified as relevant and are classified into the application areas and
 269 technology used.

270 V. RESULTS AND DISCUSSION

271 This section analyzes the research trends between 2008 and 2019 using the classification results from Section IV-C. Before
 272 describing the details, we first analyze the overall trend of publications during this period, as shown in Figure 4. The total
 273 number of papers published every year has steadily increased since 2008. Figure 4 also shows that the rate of increase has
 274 significantly grown in the last four years, i.e., from 2016 to 2019. Notably, most of the papers (62%) were published in the last




Fig. 3: Keyword blocks constructed according to PICOS strategy to determine relevance of a paper to this review




Fig. 4: Number of publications using new technologies between 2008-2019

four years (between 2016 - 2019), while 21% papers in just 2019. This trend shows the growing interest in finding alternative objective ways of assessing Parkinson's Disease, particularly in the most recent years.

The following subsections first analyze the number of papers published in each application area. Then, we focus on the various PD symptoms studied by these papers. Finally, we describe the various wearable and mobile technologies used for PD diagnosis, monitoring, and treatment. The analysis in this section can help researchers understand the change in PD research over the last few years and future directions in this area.

A. Application Areas

Wearable technology has varying levels of utility in each application area of PD. To this end, Figure 5 shows the percentage of papers published in each of the four applications used in this survey. Out of the 976 papers evaluated, 365 (37%) studies focus on diagnosis or assisting in the diagnosis of Parkinson's Disease and 350 (36%) papers are focused on monitoring of patients or prognosis of the disease and the severity of symptoms. Furthermore, 164 (17%) studies are about improving the rehabilitation process of the patients and improving their quality of life, and while 97 (10%) studies analyze the effect of




Fig. 5: Percentage of publications between 2008-2019 by application area

287 the medication and treatment on the symptoms of the patient as shown in Figure 5. These numbers show that wearable and
 288 mobile technology are most frequently used for diagnosis and monitoring of PD. In the following, we detail the trends in each
 289 application area.

290 1) **Diagnosis:** Since a correct diagnosis is of prime importance, several researchers proposed objective and inexpensive
 291 techniques based on mobile technology to augment current techniques. Figure 6(a) shows the trend in the research papers
 292 focusing on diagnosis over the last 12 years. We observe a steep increase in the number of articles focusing on the diagnosis
 293 of PD. More detailed investigation indicates that studies analyzing both motor and non-motor symptoms contributed to this
 294 increase. Raethjen et al. [38] and Zhang et al. [39] have used EEG and EMG data to characterize the tremor in PD patients.
 295 Similarly, gait analysis using smartphone accelerometers is used to differentiate PD patients with gait disorder from healthy
 296 controls [25]. Muscle activity information obtained from EMG sensors has also been used for PD diagnosis. For example,
 297 Meigal et al. [26] employ surface EMG (sEMG) to differentiate between PD subjects from healthy controls and analyze the
 298 severity of symptoms. Studies focusing on non-motor symptoms typically analyze sleep patterns and speech disorders as PD
 299 biomarkers. EMG data recorded from the chin of a sleeping PD patient to compare the rapid eye movement (REM) sleep
 300 chin EMG quantitative features between PD patients with or without REM sleep behavior disorder (RBD) [27]. Similarly,
 301 Campos-Roca et al. extracted various acoustic features from an acoustic data set of 40 healthy control and 40 PD patients [28].
 302 In another study, Tsanas et al. used four parsimonious subsets of 132 dysphonia features from an existing data set of 263
 303 samples from 43 subjects [32]. The authors show that the classification with the new dysphonia features was able to reach
 304 almost 99% accuracy.

305 In summary, these studies show that recent advances in technology combined with novel algorithms can help clinicians in
 306 developing objective measures for PD diagnosis. Table VI in Appendix-B provides a comprehensive list of the articles focusing
 307 on diagnosis for interested readers.

308 2) **Prognosis/Monitoring Disease Progression:** The assessment of the condition and severity of PD symptoms depends
 309 primarily on the clinician's judgment and the patient's feedback. However, patient feedback is subject to recall bias and
 310 subjectivity, affecting clinician's analysis. Therefore, there is a strong need for objective home-based monitoring systems to
 311 provide feedback to both doctors and patients. Wearable devices and technologies are well suited for home-based monitoring
 312 since they can continuously record the patients' movements and symptoms. 350 (36%) papers published between 2008 and
 313 2019 dealt with problems related to tracking PD patients, assisted living for patients, evaluating the severity of PD symptoms
 314 in a patient, and disease progression in general, as shown in Figure 5. Figure 6(b) shows the trend of papers published in the
 315 prognosis application area from 2008 to 2019. The number of publications starts increasing considerably faster after 2014.
 316 This growth is mainly driven by the improvements in wearable technologies in the last 3-4 years. We provide a brief overview
 317 of recent research that uses wearable devices for PD prognosis while Table V in Appendix-B provides a comprehensive list




Fig. 6: Articles published in last 12 years by PD application area. (a) Publications that are focusing on contributing to improving Diagnosis of PD, (b) Publications that are focusing on Prognosis and Monitoring of PD, its symptoms and assessing severity, (c) Publications that are focusing on Predicting Response to Treatment, (d) Publications that are focusing on improving Therapy and Rehabilitation techniques

318 of papers.

319 The papers in the prognosis application typically focus on monitoring gait parameters. For instance, Zwartjes et al. present
 320 an ambulatory monitoring system that provides a complete motor assessment of a PD patient by simultaneously analyzing
 321 motor activities and the severity of several symptoms like tremor, bradykinesia, and hypokinesia [35]. Another study in 2016
 322 proposes to quantifying tremors in Parkinson’s patients using smartwatches [40]. Similarly, Bächlin et al. propose a wearable
 323 assistant to detect FoG events during ambulatory movements [41]. In addition to monitoring, papers in the prognosis area have
 324 also focused on enabling clinical tests outside the clinic. For example, the “Timed Up and Go” test (TUG) is a commonly used
 325 clinical test to evaluate balance and mobility. Salarian et al. proposed an instrumented TUG called iTUG using portable inertial
 326 sensors [42]. More recently, researchers have focused on non-motor symptoms, such as emotions and fatigue, to assess the
 327 progression of PD. Other studies recorded facial expressions of 40 PD patients to investigate the relationship between reduced
 328 facial expressiveness and altered emotion recognition in PD [33]. Overall, these studies demonstrate the potential offered by
 329 advances in technology to enable monitoring of PD patients. Hence, the trend in Figure 6(b) is likely to continue to grow in
 330 the coming years.

331 3) **Predicting Response to Treatment:** About 10% of articles classified in Section IV-C measure the efficacy of the PD
 332 treatment in a patient. Figure 6(c) shows the trend of the number of papers published each year for predicting the response
 333 to therapy. The growth in this application area has been steady over the past decade. In general, this shows that the focus on
 334 using wearable and mobile devices for predicting response to PD treatment has not changed significantly from 2008 to 2018.
 335 We also observe a steep increase in 2019 in the number of papers focusing on predicting response to treatment. This jump
 336 may indicate a growing interest in the research community in predicting response to treatment. Table III shows a summary
 337 of the papers that focus on predicting response to treatment. At the same time, the rest of this section highlights the major
 338 treatments for PD and technology for predicting the response.

339 Levodopa medication is the most popular treatment for motor and non-motor symptoms of Parkinson’s Disease. It helps
 340 alleviate important symptoms, such as bradykinesia, rigidity, and tremors, of PD patients. Another conventional treatment
 341 methodology used by physicians is Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN). It helps in alleviating
 342 motor symptoms and reducing dopaminergic medication. Measuring the efficacy of such treatments on PD patients is important
 343 since the mechanism through which they improve cognitive or motor operations in patients with Parkinson’s Disease is not
 344 well understood. Recent studies propose theories to measure the effect of Levodopa medication using biopotential devices
 345 like EEG and EMG [43]–[45]. In contrast, Rigas et al. [46] and Pelicioni et al. [47] propose new methods of assessing PD
 346 symptoms while using wearable sensors. Moreover, other research articles like [48], [49] and [50] have proposed solutions
 347 using wearable sensors to measure the effectiveness of DBS treatment on PD patients.

348 In summary, most of the papers that focus on predicting response to treatment analyze the severity of PD symptoms before,
 349 during, and after treatment. Some of the studies also focus on understanding the mechanism through which the medication
 350 alleviates PD symptoms. Further research in this domain will help health professionals fine-tune treatment for each patient
 351 based on their response to the treatment.

352 4) **Rehabilitation:** Developing an efficient rehabilitation plan for a PD patient is crucial to manage the symptoms experienced
 353 by patients. Rehabilitation techniques may use assistive cues to help the patients in their daily activities or improve their
 354 movement. In the last 12 years, 164 papers have focused on developing therapy and rehabilitation techniques. Significant
 355 research attention has also been devoted to developing methods to alleviate motor symptoms like Freezing of gait (FoG) and
 356 tremor using auditory, haptic or vibratory cues. Table IV provides a list of papers related to Rehabilitation while we summarize
 357 recent approaches in the rest of this subsection.

358 The decline in motor and cognitive functionalities in PD patients leads to increased risk of falling, Freezing of gait, and
 359 reduced quality of life. To help with the decline in motor functions, stepping in place (SIP) training is a common rehabilitation
 360 technique [51]. Sensory cueing is another common method used for facilitating SIP for PD patients. Recorded sounds of action
 361 relevant tasks effectively reduce gait variability in PD patients without Freezing of gait (nFoG). Young et al. studied the efficacy
 362 of such auditory cues in PD patients with FoG [52]. Similarly, haptic cues are also used in various studies to unfreeze the gait
 363 in FoG episodes for PD patients [53], [54]. To cope with hand tremor, Vidya et al. [55] use a coin-type vibration motor on
 364 the patients’ wrist and a micro-controller for generating random vibration patterns by using Pulse Width Modulation.

365 In summary, the focus of researchers on improving rehabilitation strategies for PD patients has steadily increased since 2008,
 366 as shown in Figure 6(d). The growth is linear with the number of papers increasing from about two in 2008 to more than 25
 367 in 2019.

368 B. Trends in Symptoms Measured by PD Research Papers

369 A majority of exploration in the last decade has been in assessing motor symptoms since they are primarily visible in patients.
 370 Inertial data collected from IMUs in wearable devices are widely used to monitor gait parameters, tremor, motor activities, FoG
 371 events, bradykinesia, and dyskinesia (ON/OFF Stages). Force and pressure sensors placed under the shoe or in an insole sensor
 372 are used for measuring the ground reaction force, which is a popular parameter for analyzing gait. EMG sensors are used for
 373 monitoring the muscular response of a person. More sophisticated instruments like digitized tablets and smart pens are used




Fig. 7: Thermal map indicating the number the publications between 2008-2019 that measure the motor symptoms of PD application areas. The darker the color, the higher the number.




Fig. 8: Thermal map indicating the number the publications between 2008-2019 that measure the non-motor symptoms of PD application areas. The darker the color, the higher the number.

374 to analyze hand movement and pressure while writing. The heat-map in Figure 7 shows the number of times a specific motor
 375 symptom is used to develop a solution to a particular application area. Gait abnormality is the most popular motor symptom in
 376 PD assessment across all application areas except for “Predicting Response to Treatment”. The motor symptoms that are most
 377 commonly monitored among applications focusing on “Predicting Response to Treatment” are bradykinesia and dyskinesia.
 378 They primarily monitor the ON/OFF stages and evaluate the muscle activities. Tremor and Freezing of gait are common motor
 379 symptoms in a PD patient and are also used as biomarkers for objective assessment of PD. Analyzing the balance and posture
 380 of a patient is a common strategy used in prognosis and rehabilitation.

381 Figure 9 shows the trend in which the focus on gait, tremor, and other symptoms has progressed in the last decade. It can
 382 be observed that following 2012, more research studies have focused on gait than tremor, even though the number of papers
 383 for each of these symptoms kept growing. With the popularity of wearables and with the development of advanced IMUs,
 384 measuring of gait parameters became easier.

385 Many researchers are now focusing on non-motor symptoms such as cognitive impairment, dementia, and depression. These
 386 can be more disabling for a patient; hence, objective assessment is required. Analyzing neural response measurements is a
 387 common strategy used by clinicians and researchers to improve diagnosis, monitoring, and analyzing the response to treatment,
 388 as shown in Figure 8. Analyzing the cognitive activity of patients is also a strategy used in different application areas. However, it
 389 is evident from the heat-map that the amount of work focusing on severe and disabling symptoms such as dementia, depression,




Fig. 9: Articles published in last ten years measuring Gait, Tremor, and other symptoms using modern technology




Fig. 10: Number of publications using new technologies between the years 2008-2019

390 fatigue is negligible compared to the motor symptoms.

391 C. Trends in Device Usage from 2008 to 2019

392 This section evaluates the type of device used in the papers we review. Of the articles reviewed, 44% used a wearable device
 393 for collecting the data, 20% papers used biopotential devices, 10% used Audio Recording devices, 65% used Motion Capturing
 394 systems, 3% used different Cueing devices like auditory, haptic or visual cues, as shown in Figure 10. The figure shows that
 395 the wearable and biopotential devices are the most commonly used devices in the studies related to Parkinson's assessment.

396 Biopotential devices, such as EEG, ECG, EMG, EOG, have been popular in assessing the stage of a patient who has
 397 Parkinson's Disease. EEG recordings are prevalent in measuring the neural activity of a patient, which is a popular PD
 398 biomarker [38], [56]–[58]. EEG data is also useful for assessing other non-motor symptoms including sleep topics, dementia,
 399 cognitive activity, and mixed symptoms like saccades [59]–[64]. Similarly, EMG recordings are beneficial in analyzing the
 400 muscle activity, which is instrumental in detecting and assessing Parkinson's disease. [65]–[69]. Many researchers also use
 401 ECG and EOG to study the heart rate and optical movements, respectively, to assess PD in patients [70]–[72]. The growth in
 402 the number of papers using Wearables or Biopotentials is shown in Figure 11(a-b). Figure 11(a) suggests that the number of




Fig. 11: (a) The papers published between 2008 and 2019 that use Biopotential devices for PD assessment. (b) The papers published between 2008 and 2018 that use Wearable devices for PD assessment. The solid line shows the trend of the publications in the last 12 years




Fig. 12: Distribution of articles published between 2008-2019 related to the assessment of Parkinson's Disease using modern technology

papers that use biopotential devices to evaluate PD symptoms has grown at a constant rate. With the development of portable biopotential devices and wearable devices with built-in biopotential sensors, their use for PD research is expected to increase.

Section III elaborated the different devices categorized as “Wearable”. Any wireless device placed on any part of a subject's body to collect relevant data can be called a wearable device. Such devices usually have one or multiple sensors embedded in them for collecting the data. Then, the raw data is either transmitted via some communication interface, i.e., Bluetooth or Zigbee, to a processing unit or is processed on a microcontroller in the device itself. Different types of sensors, such as accelerometer, gyroscope, magnetometer, temperature, force, and pressure, have been used individually or together for PD assessment [73]–[81]. Wearable devices have also been developed to incorporate Biopotential sensors like EMG used to record muscle activity data [39], [45], [82]–[85]. Other sensors like insole force or pressure sensors have been used to evaluate the vertical ground reaction force generated when the subject is walking to assess their gait, balance, or posture [86]–[92]. Figure 11(b) shows that the number of papers published using wearable devices has increased significantly in the last 11 years and is expected to keep growing.

Device Usage Trend: The heatmap in Figure 12 shows the number of papers using each of the devices from 2008–2019. We see that the usage of all the devices has grown in recent years. The increase is significantly pronounced for wearable and biopotential devices. This increase can be attributed to advances in sensor technology, low-power processing, and machine learning algorithms. Motion capturing systems, audio recording, and smartphones are also used more frequently in the last several years, similar to wearable and biopotential devices. They are expected to be used more in the future for home monitoring applications.

Device Usage by Application Area: Figure 13 shows how each device category is used across the four applications. Almost all device categories, except cueing, are predominantly used in diagnosis and prognosis. This trend is expected since a majority of papers in this review focus on diagnosis or prognosis. When the devices are analyzed individually, we see that wearable devices are most commonly used for prognosis due to their ability to monitor patients in a free-living environment. Motion




Fig. 13: Percentage of publications between 2008-2019 using different novel technologies for PD assessment by application areas

425 tracking and video recording are also used most commonly for prognosis due to similar reasons. Biopotential devices have one
 426 of the highest usages in predicting response to therapy. Audio-recording devices are prevalent in aiding diagnosis but have not
 427 been used in predicting response to treatment. Similarly, smartphones are yet to be used in applications focused on predicting
 428 response to treatment.

429 All device modalities have been used for the rehabilitation application. However, cueing devices are the predominant mode
 430 for rehabilitation. Specifically, around 90% of the work using cueing systems focuses on improving the therapeutic strategies
 431 and rehabilitation plans. Active cueing such as vibration and auditory feedback have also been used to suppress symptoms like
 432 FoG and tremor. Different scientific studies have used visual cues to develop strategies for assisting walk of PD patients [93]–
 433 [95]. Wireless headphones have been used to give auditory feedback to patients for improved motor activity, gait training, and
 434 balance training [94], [96]–[98]. Moreover, auditory and vibratory cues have been used to help a patient break out of a freeze
 435 or suppress tremor [41], [53], [55], [99]–[103].

436 VI. CONCLUSIONS AND FUTURE WORK

437 This review presented a comprehensive overview of the technological solutions currently implemented for objective as-
 438 sessment of Parkinson’s Disease and its essential features. We reviewed 976 articles from the last decade to identify four
 439 application areas, eight device categories, and the measured symptoms. From this exploratory review, we were able to analyze
 440 the trend in which the studies in this field are moving. We conclude that in the scientific community, the emerging idea is to
 441 use unobtrusive systems for monitoring the progression of a disease from its nascent stage. One of the limitations of these
 442 studies are the limitations of available data sets. The small sample size of subjects reduces the generalizability of the solution
 443 and also hampers its credibility. Another limitation is the optimal number and the placement of sensors. Furthermore, there
 444 are arguments among the researchers on the correct features that should be extracted from the sensor signals [17]. Lastly, for
 445 automatic assessment of the symptoms, efficient algorithms are required to classify the symptoms with high accuracy. Our
 446 future work includes developing algorithms for automatic classification of the papers so that we can minimize the need for
 447 manual inspection of papers.

448 CONFLICT OF INTEREST STATEMENT

449 The authors declare that the research was conducted in the absence of any commercial or financial relationships that could
 450 be construed as a potential conflict of interest.

451 AUTHOR CONTRIBUTIONS

452 Conceptualization, R.D. and U.O.; Methodology, R.D.; Software, R.D., G.B., and S.A.; Validation, R.D., and S.A.; Formal
 453 Analysis, R.D.; Investigation, R.D.; Resources, R.D.; Data Curation, R.D. and S.A.; Writing – Original Draft Preparation, R.D.,
 454 G.B., and S.A.; Writing – Review & Editing, U.O. and H.S.; Visualization, R.D., G.B., and S.A.; Supervision, U.O. and H.S.;
 455 Project Administration, U.O.; Funding Acquisition, U.O.

456 FUNDING

457 This research was supported by NSF CAREER award CNS-1651624.

ACKNOWLEDGMENTS

This is a short text to acknowledge the contributions of specific colleagues, institutions, or agencies that aided the efforts of the authors.

SUPPLEMENTAL DATA

DATA AVAILABILITY STATEMENT

The details of all the evaluated papers are listed in the publicly shared table made available at <https://bit.ly/3rcjJgZ>.

REFERENCES

- [1] T. P. Foundation. (2019) Parkinson's Foundation: Better Lives. Together. <https://bit.ly/2Uc6ikj>, accessed March 25, 2019.
- [2] C. Marras, J. Beck, J. Bower, E. Roberts, B. Ritz, G. Ross, R. Abbott, R. Savica, S. Van Den Eeden, A. Willis *et al.*, "Prevalence of parkinson's disease across north america," *NPJ Parkinson's disease*, vol. 4, no. 1, p. 21, 2018.
- [3] S. Fahn, "Updrs development committee. unified parkinson's disease rating scale," *Recent developments in Parkinson's disease*, vol. 2, 1987.
- [4] C. G. Goetz, B. C. Tilley, S. R. Shaftman, G. T. Stebbins, S. Fahn, P. Martinez-Martin, W. Poewe, C. Sampaio, M. B. Stern, R. Dodel *et al.*, "Movement disorder society-sponsored revision of the unified parkinson's disease rating scale (mds-updrs): scale presentation and clinimetric testing results," *Movement disorders: official journal of the Movement Disorder Society*, vol. 23, no. 15, pp. 2129–2170, 2008.
- [5] M. M. Hoehn, M. D. Yahr *et al.*, "Parkinsonism: onset, progression, and mortality," *Neurology*, vol. 50, no. 2, pp. 318–318, 1998.
- [6] A. Ozanne, D. Johansson, U. Hällgren Graneheim, K. Malmgren, F. Bergquist, and M. Alt Murphy, "Wearables in epilepsy and parkinson's disease—a focus group study," *Acta Neurologica Scandinavica*, vol. 137, no. 2, pp. 188–194, 2018.
- [7] G. Bhat, R. Deb, and U. Y. Ogras, "Openhealth: Open source platform for wearable health monitoring," *IEEE Design Test*, pp. 1–1, 2019.
- [8] K. Yang, W.-X. Xiong, F.-T. Liu, Y.-M. Sun, S. Luo, Z.-T. Ding, J.-J. Wu, and J. Wang, "Objective and quantitative assessment of motor function in parkinson's disease—from the perspective of practical applications," *Annals of translational medicine*, vol. 4, no. 5, 2016.
- [9] D. F. Boland and M. Stacy, "The economic and quality of life burden associated with parkinson's disease: a focus on symptoms," *The American Journal of Managed Care*, vol. 18, no. 7 Suppl, pp. S168–75, 2012.
- [10] P. Lukowicz, T. Kirstein, and G. Tröster, "Wearable systems for health care applications," *Methods of information in medicine*, vol. 43, no. 03, pp. 232–238, 2004.
- [11] R.-B. Nagy and F. Popențiu-Vlădicescu, "Exploring the potential of internet of things systems in health care context," *eLearning & Software for Education*, vol. 3, 2018.
- [12] A. Pantelopoulou and N. G. Bourbakis, "A survey on wearable sensor-based systems for health monitoring and prognosis," *IEEE Transactions on Systems, Man, and Cybernetics, Part C (Applications and Reviews)*, vol. 40, no. 1, pp. 1–12, 2010.
- [13] G. Bhat, Y. Tuncel, S. An, H. G. Lee, and U. Y. Ogras, "An ultra-low energy human activity recognition accelerator for wearable health applications," *ACM Transactions on Embedded Computing Systems (TECS)*, vol. 18, no. 5s, pp. 1–22, 2019.
- [14] G. Bhat, Y. Tuncel, S. An, and U. Y. Ogras, "Wearable IoT Devices for Health Monitoring," in *TechConnect Briefs 2019*, 2019, pp. 357–360.
- [15] A. J. Espay, P. Bonato, F. B. Nahab, W. Maetzler, J. M. Dean, J. Klucken, B. M. Eskofier, A. Merola, F. Horak, A. E. Lang *et al.*, "Technology in parkinson's disease: Challenges and opportunities," *Movement Disorders*, vol. 31, no. 9, pp. 1272–1282, 2016.
- [16] C. Godinho, J. Domingos, G. Cunha, A. T. Santos, R. M. Fernandes, D. Abreu, N. Gonçalves, H. Matthews, T. Isaacs, J. Duffen *et al.*, "A systematic review of the characteristics and validity of monitoring technologies to assess parkinson's disease," *Journal of neuroengineering and rehabilitation*, vol. 13, no. 1, p. 24, 2016.
- [17] E. Rovini, C. Maremmani, and F. Cavallo, "How wearable sensors can support parkinson's disease diagnosis and treatment: a systematic review," *Frontiers in neuroscience*, vol. 11, p. 555, 2017.
- [18] H. Hasan, D. S. Athauda, T. Foltyniec, and A. J. Noyce, "Technologies assessing limb bradykinesia in parkinson's disease," *Journal of Parkinson's disease*, vol. 7, no. 1, pp. 65–77, 2017.
- [19] M. M. Rodgers, V. M. Pai, and R. S. Conroy, "Recent advances in wearable sensors for health monitoring," *IEEE Sensors Journal*, vol. 15, no. 6, pp. 3119–3126, 2015.
- [20] A. H. Butt, E. Rovini, D. Esposito, G. Rossi, C. Maremmani, and F. Cavallo, "Biomechanical parameter assessment for classification of parkinson's disease on clinical scale," *International Journal of Distributed Sensor Networks*, vol. 13, no. 5, p. 1550147717707417, 2017.
- [21] J.-F. Daneault, "could wearable and mobile technology improve the management of essential tremor?" *Frontiers in neurology*, vol. 9, p. 257, 2018.
- [22] A. Liberati, D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gøtzsche, J. P. Ioannidis, M. Clarke, P. J. Devereaux, J. Kleijnen, and D. Moher, "The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration," *PLoS medicine*, vol. 6, no. 7, p. e1000100, 2009.
- [23] X. Huang, J. Lin, and D. Demner-Fushman, "Evaluation of pico as a knowledge representation for clinical questions," in *AMIA annual symposium proceedings*, vol. 2006. American Medical Informatics Association, 2006, p. 359.
- [24] J. Kassubek, "Diagnostic procedures during the course of parkinson's disease," *Basal Ganglia*, vol. 4, no. 1, pp. 15–18, 2014.
- [25] M. Yoneyama, Y. Kurihara, K. Watanabe, and H. Mitoma, "Accelerometry-based gait analysis and its application to parkinson's disease assessment—part 2: A new measure for quantifying walking behavior," *IEEE Transactions on neural systems and rehabilitation engineering*, vol. 21, no. 6, pp. 999–1005, 2013.
- [26] A. I. Meigal, S. Rissanen, M. Tarvainen, P. Karjalainen, I. Iudina-Vassel, O. Airaksinen, and M. Kankaanpää, "Novel parameters of surface emg in patients with parkinson's disease and healthy young and old controls," *Journal of Electromyography and Kinesiology*, vol. 19, no. 3, pp. e206–e213, 2009.
- [27] R. Ferri, S. Fulda, F. I. Cosentino, F. Pizza, and G. Plazzi, "A preliminary quantitative analysis of rem sleep chin emg in parkinson's disease with or without rem sleep behavior disorder," *Sleep medicine*, vol. 13, no. 6, pp. 707–713, 2012.
- [28] Y. Camnos-Roca, F. Calle-Alonso, C. J. Perez, and L. Naranjo, "Computational diagnosis of parkinson's disease from speech based on regularization methods," in *2018 26th European Signal Processing Conference (EUSIPCO)*. IEEE, 2018, pp. 1127–1131.
- [29] A. A. Stone, S. Shiffman, J. E. Schwartz, J. E. Broderick, and M. R. Hufford, "Patient compliance with paper and electronic diaries," *Controlled clinical trials*, vol. 24, no. 2, pp. 182–199, 2003.
- [30] S. Papapetropoulos, "Patient diaries as a clinical endpoint in parkinson's disease clinical trials," *CNS neuroscience & therapeutics*, vol. 18, no. 5, pp. 380–387, 2012.
- [31] G. Bhat, N. Tran, H. Shill, and U. Y. Ogras, "w-har: An activity recognition dataset and framework using low-power wearable devices," *Sensors*, vol. 20, no. 18, p. 5356, 2020.
- [32] A. Tsanas, M. A. Little, P. E. McSharry, J. Spielman, and L. O. Ramig, "Novel speech signal processing algorithms for high-accuracy classification of parkinson's disease," *IEEE Transactions on biomedical engineering*, vol. 59, no. 5, pp. 1264–1271, 2012.
- [33] L. Ricciardi, M. Bologna, F. Morgante, D. Ricciardi, B. Morabito, D. Volpe, D. Martino, A. Tessitore, M. Pomponi, A. R. Bentivoglio *et al.*, "Reduced facial expressiveness in parkinson's disease: A pure motor disorder?" *Journal of the neurological sciences*, vol. 358, no. 1–2, pp. 125–130, 2015.

- 529 [34] S. Patel, K. Lorincz, R. Hughes, N. Huggins, J. Growdon, D. Standaert, M. Akay, J. Dy, M. Welsh, and P. Bonato, "Monitoring motor fluctuations in
530 patients with parkinson's disease using wearable sensors," *IEEE transactions on information technology in biomedicine*, vol. 13, no. 6, pp. 864–873,
531 2009.
- 532 [35] D. G. Zwartjes, T. Heida, J. P. Van Vugt, J. A. Geelen, and P. H. Veltink, "Ambulatory monitoring of activities and motor symptoms in parkinson's
533 disease," *IEEE transactions on biomedical engineering*, vol. 57, no. 11, pp. 2778–2786, 2010.
- 534 [36] A. L. S. De Lima, L. J. Evers, T. Hahn, L. Bataille, J. L. Hamilton, M. A. Little, Y. Okuma, B. R. Bloem, and M. J. Faber, "Freezing of gait and fall
535 detection in parkinson's disease using wearable sensors: a systematic review," *Journal of neurology*, vol. 264, no. 8, pp. 1642–1654, 2017.
- 536 [37] Á. Sánchez-Ferro, M. Elshehabi, C. Godinho, D. Salkovic, M. A. Hobert, J. Domingos, J. M. Van Uem, J. J. Ferreira, and W. Maetzler, "New methods
537 for the assessment of parkinson's disease (2005 to 2015): A systematic review," *Movement Disorders*, vol. 31, no. 9, pp. 1283–1292, 2016.
- 538 [38] J. Raethjen, R. Govindan, M. Muthuraman, F. Kopper, J. Volkman, and G. Deuschl, "Cortical correlates of the basic and first harmonic frequency of
539 parkinsonian tremor," *Clinical neurophysiology*, vol. 120, no. 10, pp. 1866–1872, 2009.
- 540 [39] B. Zhang, F. Huang, J. Liu, and D. Zhang, "A novel posture for better differentiation between parkinson's tremor and essential tremor," *Frontiers in
541 neuroscience*, vol. 12, 2018.
- 542 [40] R. Contreras, M. Huerta, G. Sagbay, C. LLumiguano, M. Bravo, A. Bermeo, R. Clotet, and A. Soto, "Tremors quantification in parkinson patients
543 using smartwatches," in *2016 IEEE Ecuador Technical Chapters Meeting (ETCM)*. IEEE, 2016, pp. 1–6.
- 544 [41] M. Bächlin, M. Plotnik, D. Roggen, I. Maidan, J. M. Hausdorff, N. Giladi, and G. Tröster, "Wearable assistant for parkinson's disease patients with
545 the freezing of gait symptom," *IEEE Trans. Information Technology in Biomedicine*, vol. 14, no. 2, pp. 436–446, 2010.
- 546 [42] A. Salarián, F. B. Horak, C. Zampieri, P. Carlson-Kuhta, J. G. Nutt, and K. Aminian, "itug, a sensitive and reliable measure of mobility," *IEEE
547 Transactions on Neural Systems and Rehabilitation Engineering*, vol. 18, no. 3, pp. 303–310, 2010.
- 548 [43] J. S. George, J. Strunk, R. Mak-McCully, M. Houser, H. Poizner, and A. R. Aron, "Dopaminergic therapy in parkinson's disease decreases cortical
549 beta band coherence in the resting state and increases cortical beta band power during executive control," *NeuroImage: Clinical*, vol. 3, pp. 261–270,
550 2013.
- 551 [44] D. M. Herz, H. R. Siebner, O. J. Hulme, E. Florin, M. S. Christensen, and L. Timmermann, "Levodopa reinstates connectivity from prefrontal to
552 premotor cortex during externally paced movement in parkinson's disease," *Neuroimage*, vol. 90, pp. 15–23, 2014.
- 553 [45] V. Ruonala, E. Pekkonen, O. Airaksinen, M. Kankaanpää, P. A. Karjalainen, and S. M. Rissanen, "levodopa-induced changes in electromyographic
554 patterns in patients with advanced parkinson's disease," *Frontiers in neurology*, vol. 9, p. 35, 2018.
- 555 [46] G. Rigas, P. Bougia, D. Baga, M. Tsipouras, A. Tzallas, E. Tripoliti, S. Tsouli, M. Chondrogiorgi, S. Konitsiotis, and D. I. Fotiadis, "A decision support
556 tool for optimal levodopa administration in parkinson's disease," in *Proceedings of the 10th IEEE International Conference on Information Technology
557 and Applications in Biomedicine*. IEEE, 2010, pp. 1–6.
- 558 [47] P. H. Pelicioni, M. A. Brodie, M. D. Latt, J. C. Menant, H. B. Menz, V. S. Fung, and S. R. Lord, "Head and trunk stability during gait before and
559 after levodopa intake in parkinson's disease subtypes," *Experimental gerontology*, vol. 111, pp. 78–85, 2018.
- 560 [48] S. D. Tabbal, M. Ushe, J. W. Mink, F. J. Revilla, A. R. Wernle, M. Hong, M. Karimi, and J. S. Perlmutter, "Unilateral subthalamic nucleus stimulation
561 has a measurable ipsilateral effect on rigidity and bradykinesia in parkinson disease," *Experimental neurology*, vol. 211, no. 1, pp. 234–242, 2008.
- 562 [49] Y. R. Fatmehsari and F. Bahrami, "Lempel-ziv complexity criteria for nonlinear analysis of gait in patients with parkinson's disease," in *2011 18th
563 Iranian Conference of Biomedical Engineering (ICBME)*. IEEE, 2011, pp. 137–141.
- 564 [50] R. Bhidayasiri, J. Sringean, C. Anan, K. Boonpang, C. Thanawattano, and K. R. Chaudhuri, "Quantitative demonstration of the efficacy of night-time
565 apomorphine infusion to treat nocturnal hypokinesia in parkinson's disease using wearable sensors," *Parkinsonism & related disorders*, vol. 33, pp.
566 S36–S41, 2016.
- 567 [51] T. Chomiak, A. Watts, N. Meyer, F. V. Pereira, and B. Hu, "A training approach to improve stepping automaticity while dual-tasking in parkinson's
568 disease: A prospective pilot study," *Medicine*, vol. 96, no. 5, 2017.
- 569 [52] W. R. Young, L. Shreve, E. J. Quinn, C. Craig, and H. Bronte-Stewart, "Auditory cueing in parkinson's patients with freezing of gait. what matters
570 most: action-relevance or cue-continuity?" *Neuropsychologia*, vol. 87, pp. 54–62, 2016.
- 571 [53] E. Jovanov, E. Wang, L. Verhagen, M. Fredrickson, and R. Fratangelo, "defog—a real time system for detection and unfreezing of gait of parkinson's
572 patients," in *2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society*. IEEE, 2009, pp. 5151–5154.
- 573 [54] S. T. Moore, H. G. MacDougall, and W. G. Ondo, "Ambulatory monitoring of freezing of gait in parkinson's disease," *Journal of neuroscience methods*,
574 vol. 167, no. 2, pp. 340–348, 2008.
- 575 [55] V. Vidya, P. Poornachandran, V. Sujadevi, and M. M. Dharmana, "Suppressing parkinson's diseases induced involuntary movements using wearables,"
576 in *2017 International Conference on Technological Advancements in Power and Energy (TAP Energy)*. IEEE, 2017, pp. 1–4.
- 577 [56] P. C. Nijssen, G. J. Brekelmans, and R. A. Roos, "Electroencephalography in autosomal dominant adult neuronal ceroid lipofuscinosis," *Clinical
578 Neurophysiology*, vol. 120, no. 10, pp. 1782–1786, 2009.
- 579 [57] N. Fogelson, M. Fernandez-del Olmo, and D. Santos-Garcia, "Contextual processing deficits in parkinson's disease: The role of the frontostriatal
580 system," *Clinical Neurophysiology*, vol. 122, no. 3, pp. 539–545, 2011.
- 581 [58] E. P. Casula, M. S. Bassi, M. C. Pellicciari, V. Ponzio, D. Veniero, A. Peppe, L. Brusa, P. Stanzione, C. Caltagirone, A. Stefani *et al.*, "Subthalamic
582 stimulation and levodopa modulate cortical reactivity in parkinson's patients," *Parkinsonism & related disorders*, vol. 34, pp. 31–37, 2017.
- 583 [59] J. R. Brazète, J.-F. Gagnon, R. B. Postuma, J.-A. Bertrand, D. Petit, and J. Montplaisir, "Electroencephalogram slowing predicts neurodegeneration in
584 rapid eye movement sleep behavior disorder," *Neurobiology of aging*, vol. 37, pp. 74–81, 2016.
- 585 [60] R. Margis, S. V. Schönwald, D. Z. Carvalho, G. J. Gerhardt, and C. R. Rieder, "Nrem sleep alpha and sigma activity in parkinson's disease: Evidence
586 for conflicting electrophysiological activity?" *Clinical Neurophysiology*, vol. 126, no. 5, pp. 951–958, 2015.
- 587 [61] J. A. Christensen, M. Zoetmulder, H. Koch, R. Frandsen, L. Arvastson, S. R. Christensen, P. Jennum, and H. B. Sorensen, "Data-driven modeling of
588 sleep eeg and eog reveals characteristics indicative of pre-parkinson's and parkinson's disease," *Journal of neuroscience methods*, vol. 235, pp. 262–276,
589 2014.
- 590 [62] R. L. Utianski, J. N. Caviness, E. C. van Straaten, T. G. Beach, B. N. Dugger, H. A. Shill, E. D. Driver-Dunckley, M. N. Sabbagh, S. Mehta, C. H.
591 Adler *et al.*, "Graph theory network function in parkinson's disease assessed with electroencephalography," *Clinical Neurophysiology*, vol. 127, no. 5,
592 pp. 2228–2236, 2016.
- 593 [63] B. Güntekin, L. Hanoğlu, D. Güner, N. H. Yılmaz, F. Çadırcı, N. Mantar, T. Aktürk, D. D. Emek-Savaş, F. F. Özer, G. Yener *et al.*, "Cognitive
594 impairment in parkinson's disease is reflected with gradual decrease of eeg delta responses during auditory discrimination," *Frontiers in psychology*,
595 vol. 9, p. 170, 2018.
- 596 [64] M. Javaid, V. Amassian, S. Glazman, A. Fesharaki, D. Stefanov, and I. Bodis-Wollner, "Cortical control of voluntary saccades in parkinson's disease
597 and pre-emptive perception," *Parkinsonism & related disorders*, vol. 18, pp. S100–S103, 2012.
- 598 [65] P. Caliendo, M. Ferrarin, M. Cioni, A. R. Bentivoglio, I. Minciotti, P. D'urso, P. A. Tonali, and L. Padua, "Levodopa effect on electromyographic
599 activation patterns of tibialis anterior muscle during walking in parkinson's disease," *Gait & posture*, vol. 33, no. 3, pp. 436–441, 2011.
- 600 [66] D. Powell, A. J. Threlkeld, X. Fang, A. Muthumani, and R. Xia, "Amplitude-and velocity-dependency of rigidity measured at the wrist in parkinson's
601 disease," *Clinical Neurophysiology*, vol. 123, no. 4, pp. 764–773, 2012.
- 602 [67] V. C. Dionisio, M. de Biagi Curtarelli, and L. A. P. S. de Souza, "Sitting movement in elderly subjects with and without parkinson's disease: A
603 biomechanical study," *Journal of Electromyography and Kinesiology*, vol. 23, no. 4, pp. 948–957, 2013.
- 604 [68] R. P. Athukorala, R. D. Jones, O. Sella, and M.-L. Huckabee, "Skill training for swallowing rehabilitation in patients with parkinson's disease," *Archives
605 of Physical Medicine and Rehabilitation*, vol. 95, no. 7, pp. 1374–1382, 2014.

- [69] N. G. Margraf, M. Rogalski, G. Deuschl, and J. P. Kuhlth-Buschbeck, "Trunk muscle activation pattern in parkinsonian camptocormia as revealed with surface electromyography," *Parkinsonism & related disorders*, vol. 44, pp. 44–50, 2017.
- [70] K. Kiyono, J. Hayano, S. Kwak, E. Watanabe, and Y. Yamamoto, "Non-gaussianity of low frequency heart rate variability and sympathetic activation: lack of increases in multiple system atrophy and parkinson disease," *Frontiers in physiology*, vol. 3, p. 34, 2012.
- [71] O. Abbasi, J. Hirschmann, L. Storz, T. E. Özkurt, S. Elben, J. Vesper, L. Wojtecki, G. Schmitz, A. Schnitzler, and M. Butz, "Unilateral deep brain stimulation suppresses alpha and beta oscillations in sensorimotor cortices," *Neuroimage*, vol. 174, pp. 201–207, 2018.
- [72] C. A. Lohnes and G. M. Earhart, "Saccadic eye movements are related to turning performance in parkinson disease," *Journal of Parkinson's disease*, vol. 1, no. 1, pp. 109–118, 2011.
- [73] L. A. Hale, J. Pal, and I. Becker, "Measuring free-living physical activity in adults with and without neurologic dysfunction with a triaxial accelerometer," *Archives of physical medicine and rehabilitation*, vol. 89, no. 9, pp. 1765–1771, 2008.
- [74] K. Harish, M. V. Rao, R. Borgohain, A. Sairam, and P. Abhilash, "Tremor quantification and its measurements on parkinsonian patients," in *2009 International Conference on Biomedical and Pharmaceutical Engineering*. IEEE, 2009, pp. 1–3.
- [75] P. M. Aubin, A. Serackis, and J. Griskevicius, "Support vector machine classification of parkinson's disease, essential tremor and healthy control subjects based on upper extremity motion," in *2012 International Conference on Biomedical Engineering and Biotechnology*. IEEE, 2012, pp. 900–904.
- [76] H. Jeon, W. Lee, H. Park, H. Lee, S. Kim, H. Kim, B. Jeon, and K. Park, "Automatic classification of tremor severity in parkinson's disease using a wearable device," *Sensors*, vol. 17, no. 9, p. 2067, 2017.
- [77] C.-C. Yang, Y.-L. Hsu, K.-S. Shih, and J.-M. Lu, "Real-time gait cycle parameter recognition using a wearable accelerometry system," *Sensors*, vol. 11, no. 8, pp. 7314–7326, 2011.
- [78] M. Mancini, A. Salarian, P. Carlson-Kuhta, C. Zampieri, L. King, L. Chiari, and F. B. Horak, "Isway: a sensitive, valid and reliable measure of postural control," *Journal of neuroengineering and rehabilitation*, vol. 9, no. 1, p. 59, 2012.
- [79] Y. A. Mustafa, J. Barton, B. O'Flynn, R. Davies, P. McCullagh, and H. Zheng, "Design of a smart insole for ambulatory assessment of gait," in *2015 IEEE 12th International Conference on Wearable and Implantable Body Sensor Networks (BSN)*. IEEE, 2015, pp. 1–5.
- [80] B. Sijobert, C. Azevedo-Coste, D. Andreu, C. Verna, and C. Geny, "Effects of sensitive electrical stimulation based cueing in parkinson's disease: a preliminary study," *European journal of translational myology*, vol. 26, no. 2, 2016.
- [81] I. Mileti, M. Germanotta, S. Alcaro, A. Pacilli, I. Imbimbo, M. Petracca, C. Erra, E. Di Sipio, I. Aprile, S. Rossi *et al.*, "Gait partitioning methods in parkinson's disease patients with motor fluctuations: A comparative analysis," in *2017 IEEE International Symposium on Medical Measurements and Applications (MeMeA)*. IEEE, 2017, pp. 402–407.
- [82] A. Hossen, M. Muthuraman, J. Raethjen, G. Deuschl, and U. Heute, "Discrimination of parkinsonian tremor from essential tremor by implementation of a wavelet-based soft-decision technique on emg and accelerometer signals," *Biomedical Signal Processing and Control*, vol. 5, no. 3, pp. 181–188, 2010.
- [83] S. M. Rissanen, M. Kankaanpää, M. P. Tarvainen, A. Y. Meigal, J. Nuutinen, I. M. Tarkka, O. Airaksinen, and P. A. Karjalainen, "Analysis of dynamic voluntary muscle contractions in parkinson's disease," *IEEE Transactions on Biomedical Engineering*, vol. 56, no. 9, pp. 2280–2288, 2009.
- [84] B. Boroojerdi, R. Ghaffari, N. Mahadevan, M. Markowitz, K. Melton, B. Morey, C. Otoul, S. Patel, J. Phillips, E. Sen-Gupta *et al.*, "Clinical feasibility of a wearable, conformable sensor patch to monitor motor symptoms in parkinson's disease," *Parkinsonism & related disorders*, 2018.
- [85] E. Lalo, J. Riff, R. Parry, M. Jabloun, J. Roussel, C.-C. Chen, M.-L. Welter, and O. Buttelli, "Design of technology and technology of design. activity analysis as a resource for a personalised approach for patients with parkinson disease," *IRBM*, vol. 37, no. 2, pp. 90–97, 2016.
- [86] A. Zhao, L. Qi, J. Li, J. Dong, and H. Yu, "A hybrid spatio-temporal model for detection and severity rating of parkinson's disease from gait data," *Neurocomputing*, vol. 315, pp. 1–8, 2018.
- [87] L. Medeiros, H. Almeida, L. Dias, M. Perkusich, and R. Fischer, "A gait analysis approach to track parkinson's disease evolution using principal component analysis," in *2016 IEEE 29th International Symposium on Computer-Based Medical Systems (CBMS)*. IEEE, 2016, pp. 48–53.
- [88] A. Jamthe, S. Chakraborty, S. K. Ghosh, and D. P. Agrawal, "An implementation of wireless sensor network in monitoring of parkinson's patients using received signal strength indicator," in *2013 IEEE International Conference on Distributed Computing in Sensor Systems*. IEEE, 2013, pp. 442–447.
- [89] C.-N. Lee, V. H. Fong, Y.-T. Chu, L. Cheng, H.-W. Chuang, and C.-Y. Lo, "A wearable device of gait tracking for parkinson's disease patients," in *2018 International Conference on Machine Learning and Cybernetics (ICMLC)*, vol. 2. IEEE, 2018, pp. 462–466.
- [90] K. Niazmand, K. Tonn, A. Kalaras, U. M. Fietzek, J.-H. Mehrkens, and T. C. Lueth, "Quantitative evaluation of parkinson's disease using sensor based smart glove," in *2011 24th International Symposium on Computer-Based Medical Systems (CBMS)*. IEEE, 2011, pp. 1–8.
- [91] M. R. Daliri, "Chi-square distance kernel of the gaits for the diagnosis of parkinson's disease," *Biomedical Signal Processing and Control*, vol. 8, no. 1, pp. 66–70, 2013.
- [92] M. S. Baby, A. Saji, and C. S. Kumar, "Parkinson's disease classification using wavelet transform based feature extraction of gait data," in *2017 International Conference on Circuit, Power and Computing Technologies (ICCPCT)*. IEEE, 2017, pp. 1–6.
- [93] J. Orlosky, Y. Itoh, M. Ranchet, K. Kiyokawa, J. Morgan, and H. Devos, "Emulation of physician tasks in eye-tracked virtual reality for remote diagnosis of neurodegenerative disease," *IEEE transactions on visualization and computer graphics*, vol. 23, no. 4, pp. 1302–1311, 2017.
- [94] Y. Baram and R. Lenger, "Gait improvement in patients with cerebral palsy by visual and auditory feedback," *Neuromodulation: Technology at the Neural Interface*, vol. 15, no. 1, pp. 48–52, 2012.
- [95] W. Buated, M. Sriyudthsak, N. Sribunruangrit, and R. Bhidayasiri, "A low-cost intervention for improving gait in parkinson's disease patients: A cane providing visual cues," *European Geriatric Medicine*, vol. 3, no. 2, pp. 126–130, 2012.
- [96] F. Casamassima, A. Ferrari, B. Milosevic, P. Ginis, E. Farella, and L. Rocchi, "A wearable system for gait training in subjects with parkinson's disease," *Sensors*, vol. 14, no. 4, pp. 6229–6246, 2014.
- [97] T. T. da Costa Capato, J. Tornai, P. Ávila, E. R. Barbosa, and M. E. P. Piemonte, "Randomized controlled trial protocol: balance training with rhythmical cues to improve and maintain balance control in parkinson's disease," *BMC neurology*, vol. 15, no. 1, p. 162, 2015.
- [98] S. D. Ringenbach, A. W. Van Gemmert, H. A. Shill, and G. E. Stelmach, "Auditory instructional cues benefit unimanual and bimanual drawing in parkinson's disease patients," *Human movement science*, vol. 30, no. 4, pp. 770–782, 2011.
- [99] P. Lorenzi, R. Rao, G. Romano, A. Kita, M. Serpa, F. Filesi, F. Irrera, M. Bologna, A. Suppa, and A. Berardelli, "Smart sensors for the recognition of specific human motion disorders in parkinson's disease," in *2015 6th International Workshop on Advances in Sensors and Interfaces (IWASI)*. IEEE, 2015, pp. 131–136.
- [100] L. Pepa, M. Capecci, F. Verdini, M. G. Ceravolo, and L. Spalazzi, "An architecture to manage motor disorders in parkinson's disease," in *2015 IEEE 2nd World Forum on Internet of Things (WF-IoT)*. IEEE, 2015, pp. 615–620.
- [101] P. J. McCandless, B. J. Evans, J. Janssen, J. Selfe, A. Churchill, and J. Richards, "Effect of three cueing devices for people with parkinson's disease with gait initiation difficulties," *Gait & posture*, vol. 44, pp. 7–11, 2016.
- [102] O. A. Cando, K. R. Hidalgo, and B. C. Palacios, "A low-cost vibratory stimulus system to mitigate freezing of gait in parkinson's disease," in *2016 IEEE ANDESCON*. IEEE, 2016, pp. 1–4.
- [103] A. Fung, E. C. Lai, and B.-C. Lee, "Usability and validation of the smarter balance system: An unsupervised dynamic balance exercises system for individuals with parkinson's disease," *IEEE Transactions on Neural Systems and Rehabilitation Engineering*, vol. 26, no. 4, pp. 798–806, 2018.
- [104] N. Most. (1999) metapub . PyPI. <https://pypi.org/project/metapub/>, accessed March 7, 2019.
- [105] S. M. Rissanen, V. Ruonala, E. Pekkonen, M. Kankaanpää, O. Airaksinen, and P. A. Karjalainen, "Signal features of surface electromyography in advanced parkinson's disease during different settings of deep brain stimulation," *Clinical Neurophysiology*, vol. 126, no. 12, pp. 2290–2298, 2015.

- [106] W. J. Teskey, M. Elhabiby, and N. El-Sheimy, “Inertial sensing to determine movement disorder motion present before and after treatment,” *Sensors*, vol. 12, no. 3, pp. 3512–3527, 2012.
- [107] M. Jenkins, Q. Almeida, S. Spaulding, R. Van Oostveen, J. Holmes, A. M. Johnson, and S. Perry, “Plantar cutaneous sensory stimulation improves single-limb support time, and emg activation patterns among individuals with parkinson’s disease,” *Parkinsonism & related disorders*, vol. 15, no. 9, pp. 697–702, 2009.
- [108] P. Ginis, R. Pirani, S. Basaia, A. Ferrari, L. Chiari, E. Heremans, C. G. Canning, and A. Nieuwboer, “Focusing on heel strike improves toe clearance in people with parkinson’s disease: an observational pilot study,” *Physiotherapy*, vol. 103, no. 4, pp. 485–490, 2017.
- [109] J. C. Vasquez-Correa, T. Arias-Vergara, J. Orozco-Arroyave, B. M. Eskofier, J. Klucken, and E. Noth, “Multimodal assessment of parkinson’s disease: a deep learning approach,” *IEEE journal of biomedical and health informatics*, 2018.
- [110] S. Haider Shah, K. Iqbal, and A. Riaz, “Constrained optimization-based extreme learning machines with bagging for freezing of gait detection,” *Big Data and Cognitive Computing*, vol. 2, no. 4, p. 31, 2018.
- [111] W. Nanhoe-Mahabier, J. Allum, E. Pasman, S. Overeem, and B. Bloem, “The effects of vibrotactile biofeedback training on trunk sway in parkinson’s disease patients,” *Parkinsonism & related disorders*, vol. 18, no. 9, pp. 1017–1021, 2012.
- [112] E. van Wegen, C. de Goede, G. Kwakkel, and J. van Kordelaar, “Sensor assisted self-management in parkinson’s disease: A feasibility study of ambulatory posture detection and feedback to treat stooped posture,” *Parkinsonism & related disorders*, vol. 46, pp. S57–S61, 2018.
- [113] W. O. C. Lopez, C. A. E. Higuera, E. T. Fonoff, C. de Oliveira Souza, U. Albicker, and J. A. E. Martinez, “Listenmee® and listenmee® smartphone application: synchronizing walking to rhythmic auditory cues to improve gait in parkinson’s disease,” *Human movement science*, vol. 37, pp. 147–156, 2014.
- [114] S. Wan, Y. Liang, Y. Zhang, and M. Guizani, “Deep multi-layer perceptron classifier for behavior analysis to estimate parkinson’s disease severity using smartphones,” *IEEE Access*, vol. 6, pp. 36 825–36 833, 2018.
- [115] L. A. Sanchez-Perez, L. P. Sanchez-Fernandez, A. Shaout, J. M. Martinez-Hernandez, and M. J. Alvarez-Noriega, “Rest tremor quantification based on fuzzy inference systems and wearable sensors,” *International journal of medical informatics*, vol. 114, pp. 6–17, 2018.
- [116] À. Bayés, A. Samà, A. Prats, C. Pérez-López, M. Crespo-Maraver, J. M. Moreno, S. Alcaine, A. Rodriguez-Moliner, B. Mestre, P. Quispe *et al.*, “A ‘holter’ for parkinson’s disease: Validation of the ability to detect on-off states using the rempark system,” *Gait & posture*, vol. 59, pp. 1–6, 2018.
- [117] J. A. Robichaud, K. D. Pfann, S. Leurgans, D. E. Vaillancourt, C. L. Comella, and D. M. Corcos, “Variability of emg patterns: a potential neurophysiological marker of parkinson’s disease?” *Clinical neurophysiology*, vol. 120, no. 2, pp. 390–397, 2009.
- [118] M. Memedi, A. Sadikov, V. Groznik, J. Žabkar, M. Možina, F. Bergquist, A. Johansson, D. Haubenberger, and D. Nyholm, “Automatic spiral analysis for objective assessment of motor symptoms in parkinson’s disease,” *Sensors*, vol. 15, no. 9, pp. 23 727–23 744, 2015.
- [119] J. Dietz, M. Bradley, J. Jones, M. Okun, W. Perlstein, and D. Bowers, “The late positive potential, emotion and apathy in parkinson’s disease,” *Neuropsychologia*, vol. 51, no. 5, pp. 960–966, 2013.
- [120] S. Umesh, U. Asokan, T. Srinivas *et al.*, “Parkinsonian hand tremor measurement device based on fiber bragg grating sensor,” in *2015 International Conference on Smart Sensors and Systems (IC-SSS)*. IEEE, 2015, pp. 1–3.
- [121] V. Annese, G. Mezzina, V. Gallo, V. Scarola, and D. De Venuto, “Wearable platform for automatic recognition of parkinson disease by muscular implication monitoring,” in *2017 7th IEEE International Workshop on Advances in Sensors and Interfaces (IWASI)*. IEEE, 2017, pp. 150–154.
- [122] J. C. Ayena, M. J. Otis, B.-A. Menelas *et al.*, “An efficient home-based risk of falling assessment test based on smartphone and instrumented insole,” in *2015 IEEE International Symposium on Medical Measurements and Applications (MeMeA) Proceedings*. IEEE, 2015, pp. 416–421.
- [123] R. Soubra, M. O. Diab, and B. Moslem, “Identification of parkinson’s disease by using multichannel vertical ground reaction force signals,” in *2016 International Conference on Bio-engineering for Smart Technologies (BioSMART)*. IEEE, 2016, pp. 1–4.
- [124] H. Garn, C. Coronel, M. Waser, G. Caravias, and G. Ransmayr, “Differential diagnosis between patients with probable alzheimer’s disease, parkinson’s disease dementia, or dementia with lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features,” *Journal of Neural Transmission*, vol. 124, no. 5, pp. 569–581, 2017.
- [125] C. Kotsavasiloglou, N. Kostikis, D. Hristu-Varsakelis, and M. Arnaoutoglou, “Machine learning-based classification of simple drawing movements in parkinson’s disease,” *Biomedical Signal Processing and Control*, vol. 31, pp. 174–180, 2017.
- [126] L. Ghosh, S. Parui, P. Rakshit, and A. Konar, “Eeg analysis for working memory modeling in face recognition task,” in *2017 Third International Conference on Research in Computational Intelligence and Communication Networks (ICRCICN)*. IEEE, 2017, pp. 33–38.
- [127] D. Phan, M. Horne, P. Pathirana, and P. Farzanehfar, “Measurement of axial rigidity and postural instability using wearable sensors,” *Sensors*, vol. 18, no. 2, p. 495, 2018.
- [128] M. Yokoe, R. Okuno, T. Hamasaki, Y. Kurachi, K. Akazawa, and S. Sakoda, “Opening velocity, a novel parameter, for finger tapping test in patients with parkinson’s disease,” *Parkinsonism & related disorders*, vol. 15, no. 6, pp. 440–444, 2009.

APPENDIX A DATA COLLECTION

The methodologies used for downloading the data from the four online databases are also different. The documents were exported in comma-separated values (CSV) format from IEEE Xplore, tab-delimited format from MDPI and BibTex format from Science Direct. While, for PubMed Central, we used a Python-based API, Metapub [104] for an automated search. The information extracted from all of the databases were accumulated and stored together in a .CSV file.

APPENDIX B LIST OF PAPERS IN EACH APPLICATION AREA

Tables III–VI below lists the paper in each application area discussed in Section V-A.

APPENDIX C KEYWORDS USED FOR AUTOMATED FILTERING

The first keyword block has 10 keywords related to the disease: “Parkinson”, “Parkinson’s Disease”, “Bradykinesia”, “Dyskinesia”, “Levodopa”, “Freezing of gait”.

The second block is made of 7 keywords to exclude non-human studies from the study: “Rats”, “Primates”, “Marmoset”, “Monkeys”, “Mice”, “Mouse”, “Animal”.

The third keyword block has 66 technology terms related to Parkinson’s Disease assessment: (i.e., “Acceleration”, “Accelerometer”, “Gyroscope”, “Magnetometer”, “Gyro”, “Acc”, “Exoskeleton device”, “Inertial sensor”, “Video recording”, “Video camera”, “Camera”, “EHealth”, “Technology”, “Remote monitoring”, “Home monitoring”, “Telemedicine”, “Mobile phone”, “Mobile application”, “Precision medicine”, “Digital health”, “Inertial Measurement Unit”, “IMU”, “Wearable”, “Magneto inertial sensor”, “Sensor”, “Force plate”, “Force sensor”, “Pressure sensor”, “Gait mat”, “Smartphone”, “Augmented reality”, “Kinect”, “VICON”, “ECG”, “EEG”, “EMG”, “EOG”, “MEG”, “Electrocardiography”, “Electroencephalography”, “Electromyography”, “Electrooculography”, “Magnetoencephalography”, “Machine learning”, “Classification”, “Auditory cue”, “Auditory cueing”, “Visual cue”, “Ha[ftic

752 cue”, “Vibration”, “Gait classification”, “Insole sensors”, “Leap motion”, “Computer vision”, “Supervised learning”, “Neural networks”, “Speech disorder”,
753 “Music therapy”, “Smart application”, “Smartphone application”, “Smart watch”, “Smart pen”, “Touchscreen”, “Digitized tablet”, “Fitness band”, “Optical
754 motion capturing system”).

755 **The last keyword block has 11 technology terms related to Parkinson’s Disease treatment, which we have excluded from our review** (i.e., “Positron
756 emission tomography”, “Single-photon emission computed tomography”, “Magnetic Resonance Imaging”, “Deep Brain Stimulation”, “Transcranial”, “Neu-
757 roimaging”, “Brain imaging”, “fmri”, “SPECT”, “PET”, “MRI”). The keyword blocks were used based on an earlier review [37]

TABLE III: Papers about Predicting Response to Treatment

Reference	Year	Application	Aspect Area	Device	Additional Device	Sensors	No of Subjects (n)
Jobi S. George et al. [43]	2013	Predicting Response to treatment	Bradykinesia and Dyskinesia	Biopotential		EEG	$10 < n \leq 20$
Damian M. Herz et al. [44]	2014	Predicting Response to treatment	EEG Signals	Biopotential		EEG	$10 < n \leq 20$
Veneri Ruonala et al. [45]	2018	Predicting Response to treatment	Muscle activity	Wearable	Biopotential	EMG	$10 < n \leq 20$
George Rigas et al. [46]	2010	Predicting Response to treatment	EEG Signals	Biopotential		EEG	u/k
Paulo H. S Pelicioni et al. [47]	2018	Predicting Response to treatment	Gait, Posture, Balance	Wearable		Accelerometer	> 30
Samer D. Tabbal et al. [48]	2008	Predicting Response to treatment	Limb movements	Wearable		Force sensor, Gyroscope	> 30
Y. Rakhshani Fatmehsari et al. [49]	2011	Predicting Response to treatment	Gait	Wearable		Gyroscope, Accelerometer	≤ 10
Roongroj Bhidayasiri et al. [50]	2016	Predicting Response to treatment	Nocturnal Hypokinesia	Wearable		Accelerometer, Gyroscope	≤ 10
Veneri Ruonala et al. [45]	2018	Predicting Response to treatment	EMG Signal	Wearable	Biopotential	EMG	
Saara M. Rissanen et al. [105]	2015	Predicting Response to treatment	EMG Signal	Wearable	Biopotential	EMG, Accelerometer	
Westley JE Teskey et al. [106]	2012	Predicting Response to treatment	Bradykinesia and Dyskinesia	Wearable		Accelerometer, Gyroscope	$20 \leq n \leq 30$

TABLE IV: Papers about Rehabilitation

Reference	Year	Application	Aspect Area	Device	Additional Device	Sensor/Actuator	No of Subjects
Taylor Chomiak et al. [51]	2017	Rehabilitation	Limb movements	Cueing	Wearable	Audio cue	$10 < n \leq 20$
William R. Young et al. [52]	2016	Rehabilitation	Freezing of Gait	Cueing		Audio cue	$10 < n \leq 20$
E. Jovanov et al. [53]	2009	Rehabilitation	Freezing of Gait	Wearable	Cueing	Audio cue, Accelerometer, Gyroscope	≤ 10
Steven T. Moore et al. [54]	2008	Rehabilitation	Gait,Freezing of Gait	Wearable		Accelerometer	$10 < n \leq 20$
M.E. Jenkins et al. [107]	2009	Rehabilitation	Muscle activity	Biopotential		EMG	> 30
Vishnu Vidya et al. [55]	2017	Rehabilitation	Tremor	Cueing		Vibration cue	u/k
Pieter Gimis et al. [108]	2017	Rehabilitation	Gait	Motion Tracker		Motion capture	≤ 10
Juan Camilo Vasquez-Correa et al. [109]	2018	Rehabilitation	Gait, Speech topics, Handwriting	Wearable	Audio Recording, Other	Touchscreen, Microphone, Accelerometer, Gyroscope	
Syed Haidar Shah et al. [110]	2018	Rehabilitation	Freezing of Gait	Wearable		Accelerometer, Gyroscope	
W Nanhoe-Mahabier et al. [111]	2012	Rehabilitation	Balance	Wearable	Cueing	Gyroscope, Vibration cue	$10 \leq n \leq 20$
EEH van Wegen et al. [112]	2018	Rehabilitation	Posture,Balance	Wearable	Cueing	Accelerometer, Vibration cue	
William Omar Contreras Lopez et al. [113]	2014	Rehabilitation	Gait	Wearable	Cueing	Audio cue, Accelerometer	
Filippo Casamassima et al. [96]	2014	Rehabilitation	Gait	Wearable	Smartphone,Cueing	Accelerometer,Gyroscope, Magnetometer,Audio cue	

TABLE V: Papers about Prognosis or Monitoring of Disease Progression & Severity of Symptoms

Reference	Year	Application	Aspect Area	Device	Additional Device	Sensor/Actuator	No of Subjects
Daphne G. M. Zwartjes et al. [35]	2010	Prognosis/Monitoring Disease Progression	Limb movements, Tremor, Movement disorder	Wearable	Video Recording	Accelerometer, Gyroscope, Video camera	$10 < n \leq 20$
R. Contreras et al. [40]	2016	Prognosis/Monitoring Disease Progression	Tremor	Wearable	Smartphone	Accelerometer, Gyroscope	$10 < n \leq 20$
Shaohua Wan et al. [114]	2018	Prognosis/Monitoring Disease Progression	Speech topics, ADL	Smartphone		Accelerometer, Microphone	uk
Luis A. Sanchez-Perez et al. [115]	2018	Prognosis/Monitoring Disease Progression	Tremor	Wearable		Accelerometer, Gyroscope, Magnetometer	> 30
M Bächlin et al. [41]	2010	Prognosis/Monitoring Disease Progression	Gait, Freezing of Gait	Wearable	Cueing	Accelerometer, Audio cue	≤ 10
Àngels Bayés et al. [116]	2018	Prognosis/Monitoring Disease Progression	Bradykinesia and Dyskinesia	Wearable	Smartphone	Accelerometer	u/k
Arash Salarian et al. [108]	2010	Prognosis/Monitoring Disease Progression	Posture, Gait	Wearable		Accelerometer, Gyroscope	$10 < n \leq 20$
JA Robichaud et al. [117]	2009	Prognosis/Monitoring Disease Progression	EMG Signal	Biopotential		EMG	$20 < n \leq 30$
Mevludin Memedi et al. [118]	2015	Prognosis/Monitoring Disease Progression	Handwriting	Other		Touchscreen	> 30
J Dietz et al. [119]	2013	Prognosis/Monitoring Disease Progression	Emotions, Depression	Biopotential		EEG	$10 < n \leq 20$
Lucia Ricciardi et al. [33]	2015	Prognosis/Monitoring Disease Progression	Emotions	Video Recording		Video camera	> 30
Shyamal Patel et al. [34]	2009	Prognosis/Monitoring Disease Progression	Tremor, Bradykinesia and Dyskinesia	Wearable	Video Recording	Accelerometer, Video camera	$10 < n \leq 20$

TABLE VI: Papers about Diagnosis, Early Diagnosis and Differential Diagnosis

Reference	Year	Applicaton	Aspect Area	Device	Additional Device	Sensors	No of Subjects (n)
Jan Raethjen et al. [38]	2009	Diagnosis	EEG signals, EMG signals	Biopotential		EEG, EMG	$20 < n \leq 30$
Mitsuru Yoneyama et al. [25]	2013	Diagnosis	Gait	Wearable		Accelerometer	≤ 10
Strivani Padma G et al. [120]	2015	Diagnosis	Tremor	Other		Fiber Bragg Grating Tremor Measurement (FBGTM)	uk
Bin Zhang et al. [39]	2018	Diagnosis	Tremor	Biopotential	Wearable	Accelerometer,EMG	> 30
VF Annese et al. [121]	2018	Diagnosis	Gait, EMG Signal	Biopotential		Accelerometer,EMG	≤ 10
A.Iu Meigal et al. [26]	2009	Diagnosis	EMG Signal	Biopotential		EMG	$10 < n \leq 20$
Johannes C Ayena et al. [122]	2015	Diagnosis	Balance	Biopotential	Smartphone	Force sensor	$20 < n \leq 30$
R Soubra et al. [123]	2018	Diagnosis	Gait	Wearable		Force sensor	uk
Raffaele Ferri et al. [27]	2012	Diagnosis	Sleep Topics	Biopotential		EMG	$20 < n \leq 30$
Heinrich Garn et al. [124]	2017	Diagnosis	Dementia	Biopotential		EEG	> 30
Yolanda Cammos-Roca et al. [28]	2018	Diagnosis	Speech Topics	Audio Recording		Microphone	> 30
Athanasios Tsanas et al. [32]	2012	Diagnosis	Speech Topics	Audio Recording		Microphone	> 30
Kotsavasiloglou C et al. [125]	2017	Diagnosis	Handwriting	Other		Touch screen	$20 < n \leq 30$
Lidia Ghosh et al. [126]	2017	Diagnosis	Cognitive Activity	Biopotential		EEG	$20 < n \leq 30$
Dung Phan et al. [127]	2018	Diagnosis	Bradykinesia and Dyskinesia	Wearable		Accelerometer, Gyroscope	
M. Yokoe et al. [128]	2009	Diagnosis	Limb movements	Wearable		Accelerometer, Touch sensor	